Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Conditions: Breast Adenocarcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Ref ractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Belinostat; Drug: Carfilzomib; Biological: Daratumumab; Drug: Fludeoxyglucose F-18; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Biological: Obinutuzumab; Biological: Pembrolizumab; Procedure: Positro n Emission Tomography; Biological: Rituximab; Drug: Romidepsin; Other: Saline; Biological: Trastuzumab Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cutaneous T cell lymphoma | Herceptin | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan